New antibody targets hidden plasma cells to treat kidney disease

NCT ID NCT04893096

Completed Disease control Sponsor: Mario Negri Institute for Pharmacological Research Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This phase 2 trial tests felzartamab (MOR202), an antibody that targets CD38 on plasma cells, in people with membranous nephropathy who did not improve with rituximab or similar therapies. The goal is to reduce protein leakage in urine and achieve remission of nephrotic syndrome. Participants receive nine doses over 24 weeks, and researchers monitor changes in kidney function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Felzartamab (MOR202)
What this could lead to: If successful, this could offer a new treatment option for people with membranous nephropathy who do not respond to standard therapies like rituximab.
What could go wrong: This is a small, early-phase trial with only 10 participants. The drug may not work for everyone, and side effects from targeting plasma cells are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MEMBRANOUS NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

membranous glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MEMBRANOUS NEPHROPATHY

Contacts and locations

Show contact details

Locations

ASST HPG23 - Unità di Nefrologia

Bergamo, BG, 24100, Italy
Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò"

Ranica, BG, 24020, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.